241 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Acquired by Private Ocean LLC

Private Ocean LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 241 shares of the biotechnology company’s stock, valued at approximately $36,000.

Several other institutional investors have also added to or reduced their stakes in ASND. GAMMA Investing LLC bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC boosted its holdings in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares during the period. EverSource Wealth Advisors LLC increased its stake in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter. Barometer Capital Management Inc. bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $126,000. Finally, Legato Capital Management LLC purchased a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at about $204,000.

Ascendis Pharma A/S Stock Up 0.7 %

ASND traded up $0.98 on Friday, hitting $136.38. The company had a trading volume of 260,115 shares, compared to its average volume of 294,946. The business’s fifty day simple moving average is $132.36 and its 200 day simple moving average is $137.75. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The company has a market cap of $7.94 billion, a PE ratio of -14.19 and a beta of 0.59.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. The company had revenue of $103.11 million during the quarter, compared to analysts’ expectations of $85.72 million. On average, analysts anticipate that Ascendis Pharma A/S will post -5.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ASND shares. TD Cowen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating and lifted their target price for the company from $156.00 to $175.00 in a research note on Tuesday. Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Finally, Morgan Stanley boosted their price target on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 16th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $179.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.